Chemotherapy Resistance Molecular Mechanism in Small Cell Lung Cancer.

Abstract

The malignancy of small cell lung cancer (SCLC) is the highest amongst all lung cancer types. It is characterized by rapid growth, early occurrence of distant sites metastasis, poor survival rates and is initially sensitive to chemotherapy and radiotherapy. However, most patients eventually relapse or disease progresses because of chemotherapy resistance. Because of lack of effective second-line therapies, the prognosis of SCLC patients is usually poor. For the development of novel therapies, it is necessary to understand the mechanisms of chemotherapy resistance in SCLC. The mechanism is complex, because multiple factors could lead to chemotherapy resistance. An overview of multiple events triggering the formation of chemotherapy resistance phenotypes of SCLC cells is discussed.

• Authors: Jun Zhou, Zhaopei Li, Jun Li, Binbin Gao, Wei Song
• Journal: Current molecular medicine (Curr Mol Med) Vol. 19 Issue 3 Pg. 157-163 ( 2019) ISSN: 1875-5666 [Electronic] Netherlands
• PMID: 30813876 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Chemical References

• ATP Binding Cassette Transporter, Subfamily B, Member 1
• Antineoplastic Agents
• Biomarkers
• Multidrug Resistance-Associated Proteins

Topics

• ATP Binding Cassette Transporter, Subfamily B, Member 1 (genetics, metabolism)
• Animals
• Antineoplastic Agents (pharmacology, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Biomarkers
• DNA Repair
• Drug Resistance, Neoplasm (genetics)
• Gene Expression
• Gene Expression Regulation, Enzymologic
• Gene Expression Regulation, Neoplastic
• Humans
• Lung Neoplasms (drug therapy, genetics, metabolism)
• Multidrug Resistance-Associated Proteins (genetics, metabolism)
• Small Cell Lung Carcinoma (drug therapy, genetics, metabolism)